Experiencia con vismodegib en carcinoma basocelular avanzado en un centro oncológico.

Citation data:

Actas dermo-sifiliograficas, ISSN: 1578-2190, Vol: 109, Issue: 9, Page: 813-820

Publication Year:
2018
Captures 1
Readers 1
Citations 2
Citation Indexes 2
PMID:
30055751
DOI:
10.1016/j.ad.2018.06.003
Author(s):
Bernia, E; Llombart, B; Serra-Guillén, C; Bancalari, B; Nagore, E; Requena, C; Calomarde, L; Diago, A; Lavernia, J; Traves, V; Guillén, C; Sanmartín, O Show More Hide
Publisher(s):
Elsevier BV
Tags:
Medicine
article description
Vismodegib is the first selective Hedgehog inhibitor approved for the treatment of locally advanced and metastatic basal cell carcinoma (BCC). In this article, we describe our experience with the use of this drug to treat advanced and/or multiple BCCs at a cancer center over 5 years.